ELECTROTRANSFER OF CYTOKINE GENES FOR CANCER TREATMENT
Abstract
Keywords
Full Text:
PDFReferences
Antony, G. K., & Dudek, A. Z. (2010). Interleukin 2 in cancer therapy. Current Medicinal Chemistry, 17(29), 3297-3302. doi:BSP/CMC/E-Pub/ 207 [doi]
Baginska, J., Viry, E., Paggetti, J., Medves, S., Berchem, G., Moussay, E., & Janji, B. (2013). The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Frontiers in Immunology, 4, 490. doi:10.3389/fimmu.2013.00490 [doi]
Bodles-Brakhop, A. M., Heller, R., & Draghia-Akli, R. (2009). Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: Current clinical developments. Molecular Therapy: The Journal of the American Society of Gene Therapy, 17(4), 585-592. doi:10.1038/mt.2009.5 [doi]
Bonehill, A., Tuyaerts, S., Van Nuffel, A. M., Heirman, C., Bos, T. J., Fostier, K., . . . Thielemans, K. (2008). Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Molecular Therapy : The Journal of the American Society of Gene Therapy, 16(6), 1170-1180. doi:10.1038/mt.2008.77 [doi]
Burgain-Chain, A., & Scherman, D. (2013). DNA electrotransfer: An effective tool for gene therapy. In F. Martin (Ed.), Gene therapy (). Rijeka: InTech. doi:10.5772/52528 Retrieved from https://doi.org/10.5772/52528
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., . . . Heller, R. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(36), 5896-5903. doi:10.1200/JCO.2007.15.6794 [doi]
Daud, A., Algazi, A. P., Ashworth, M. T., Fong, L., Lewis, J., Chan, S. E., . . . Bhatia, S. (2014). Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. Jco, 32(15), 9025-9025. doi:10.1200/jco.2014.32.15_suppl.9025
Dranoff, G. (2004). Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews.Cancer, 4(1), 11-22. doi:10.1038/nrc1252 [doi]
Favard, C., Dean, D. S., & Rols, M. P. (2007). Electrotransfer as a non viral method of gene delivery. Current Gene Therapy, 7(1), 67-77.
Ferrantini, M., & Belardelli, F. (2000). Gene therapy of cancer with interferon: Lessons from tumor models and perspectives for clinical applications doi:https://doi.org/10.1006/scbi.2000.0333
Floros, T., & Tarhini, A. A. (2015). Anticancer cytokines: Biology and clinical effects of interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Seminars in Oncology, 42(4), 539-548. doi:10.1053/j.seminoncol.2015.05.015 [doi]
Heller, L. C., & Heller, R. (2006). In vivo electroporation for gene therapy. Human Gene Therapy, 17(9), 890-897. doi:10.1089/hum.2006.17.890 [doi]
Heller, R., & Heller, L. C. (2015). Gene electrotransfer clinical trials. Advances in Genetics, 89, 235-262. doi:10.1016/bs.adgen.2014.10.006 [doi]
Jiang, J., Yamato, E., & Miyazaki, J. (2001). Intravenous delivery of naked plasmid DNA for in vivo cytokine expression. Biochemical and Biophysical Research Communications, 289(5), 1088-1092. doi:10.1006/bbrc.2001.6100 [doi]
Kalb, M. L., Glaser, A., Stary, G., Koszik, F., & Stingl, G. (2012). TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: Mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. Journal of Immunology (Baltimore, Md.: 1950), 188(4), 1583-1591. doi:10.4049/jimmunol.1102437 [doi]
Kanduser, M., Miklavcic, D., & Pavlin, M. (2009). Mechanisms involved in gene electrotransfer using high- and low-voltage pulses--an in vitro study. Bioelectrochemistry (Amsterdam, Netherlands), 74(2), 265-271. doi:10.1016/j.bioelechem.2008.09.002 [doi]
Kishida, T., Asada, H., Itokawa, Y., Yasutomi, K., Shin-Ya, M., Gojo, S., . . . Mazda, O. (2003). Electrochemo-gene therapy of cancer: Intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Molecular Therapy : The Journal of the American Society of Gene Therapy, 8(5), 738-745. doi:S1525-0016(03)00279-X [pii]
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., . . . Yu, H. (2009). Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell, 15(2), 114-123. doi:10.1016/j.ccr.2008.12.018 [doi]
Lucas, M. L., Heller, L., Coppola, D., & Heller, R. (2002). IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Molecular Therapy : The Journal of the American Society of Gene Therapy, 5(6), 668-675. doi:10.1006/mthe.2002.0601 [doi]
Marrero, B., Shirley, S., & Heller, R. (2014). Delivery of interleukin-15 to B16 melanoma by electroporation leads to tumor regression and long-term survival. Technology in Cancer Research & Treatment, 13(6), 551-560. doi:10.7785/tcrtexpress.2013.600252 [doi]
Miklavcic, D., Mali, B., Kos, B., Heller, R., & Sersa, G. (2014). Electrochemotherapy: From the drawing board into medical practice. Biomedical Engineering Online, 13(1), 29-925X-13-29. doi:10.1186/1475-925X-13-29 [doi]
Mir, L. M., Bureau, M. F., Rangara, R., Schwartz, B., & Scherman, D. (1998). Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. Comptes Rendus De L'Academie Des Sciences.Serie III, Sciences De La Vie, 321(11), 893-899. doi:S0764446999800031 [pii]
Neumann, E., Schaefer-Ridder, M., Wang, Y., & Hofschneider, P. H. (1982). Gene transfer into mouse lyoma cells by electroporation in high electric fields. The EMBO Journal, 1(7), 841-845.
Nishi, T., Yoshizato, K., Yamashiro, S., Takeshima, H., Sato, K., Hamada, K., . . . Ushio, Y. (1996). High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Research, 56(5), 1050-1055.
Okamura, H., Nagata, K., Komatsu, T., Tanimoto, T., Nukata, Y., Tanabe, F., . . . Fukuda, S. (1995). A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infection and Immunity, 63(10), 3966-3972.
Pizza, G., Severini, G., Menniti, D., De Vinci, C., & Corrado, F. (1984). Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. preliminary report. International Journal of Cancer, 34(3), 359-367.
Richards, J. M., Gonzalez, R., Schwarzenberger, P., Whitman, E., Stardal, K., Westhoff, C., . . . Selk, L. (2007). Phase I trial of IL-2 plasmid DNA with electroporation in metastatic melanoma. Jco, 25(18), 8578-8578. doi:10.1200/jco.2007.25.18_suppl.8578
Rols, M. P. (2008). Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods in Molecular Biology (Clifton, N.J.), 423, 19-33. doi:10.1007/978-1-59745-194-9_2 [doi]
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., . . . Vetto, J. T. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. The New England Journal of Medicine, 313(23), 1485-1492. doi:10.1056/NEJM198512053132327 [doi]
Schmidt-Wolf, I. G., Finke, S., Trojaneck, B., Denkena, A., Lefterova, P., Schwella, N., . . . Huhn, D. (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer, 81(6), 1009-1016. doi:10.1038/sj.bjc.6690800 [doi]
Shirley, S. A. (2017). Delivery of cytokines using gene electrotransfer. In D. MiklavÄiÄ (Ed.), Handbook of electroporation (pp. 1755-1768). Cham: Springer International Publishing. doi:10.1007/978-3-319-32886-7_189 Retrieved from https://doi.org/10.1007/978-3-319-32886-7_189
Showalter, A., Limaye, A., Oyer, J. L., Igarashi, R., Kittipatarin, C., Copik, A. J., & Khaled, A. R. (2017). Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine, 97, 123-132. doi:S1043-4666(17)30153-9 [pii]
Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., . . . Nelson, W. G. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Research, 59(20), 5160-5168.
Vacchelli, E., Aranda, F., Bloy, N., Buque, A., Cremer, I., Eggermont, A., . . . Galluzzi, L. (2015). Trial watch-immunostimulation with cytokines in cancer therapy. Oncoimmunology, 5(2), e1115942. doi:10.1080/2162402X.2015.1115942 [doi]
Verbik, D., & Joshi, S. (1995). Immune cells and cytokines - their role in cancer-immunotherapy (review). International Journal of Oncology, 7(2), 205-223.
Vonderheide, R. H., Aggarwal, C., Bajor, D. L., Goldenberg, J., Loch, C., Lee, J. C., . . . Bagarazzi, M. L. (2015). Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy. Jco, 33(15), TPS3104-TPS3104. doi:10.1200/jco.2015.33.15_suppl.tps3104
Weinstein-Marom, H., Pato, A., Levin, N., Susid, K., Itzhaki, O., Besser, M. J., . . . Gross, G. (2016). Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants. Journal of Immunotherapy (Hagerstown, Md.: 1997), 39(2), 60-70. doi:10.1097/CJI.0000000000000109 [doi]
Yarmush, M. L., Golberg, A., Sersa, G., Kotnik, T., & Miklavcic, D. (2014). Electroporation-based technologies for medicine: Principles, applications, and challenges. Annual Review of Biomedical Engineering, 16, 295-320. doi:10.1146/annurev-bioeng-071813-104622 [doi]
DOI: http://dx.doi.org/10.12955/cbup.v6.1291
Refbacks
- There are currently no refbacks.
Print ISSN 1805-997X, Online ISSN 1805-9961
(c) 2018 CBU Research Institute s.r.o.
For more information on the conference visit cbuic.cz